Bispecific antibody and chemokine receptor constructs
AssigneeMicromet AG
InventorsMatthias Mack, Detlef Schlondorff, Michael Spring
Life of this patent
Estimating the term…
Loading patent…
AssigneeMicromet AG
InventorsMatthias Mack, Detlef Schlondorff, Michael Spring
Estimating the term…
The invention is directed to chimeric polypeptides, e.g., bispecific antibodies, comprising a chemokine receptor binding domain and a T cell surface polypeptide or cell toxin binding domain, nucleic acids that encode them, and methods of making and using them. The chimeric polypeptides of the invention can include, be bound to, or attached to, a cell toxin. The invention is also directed to pharmaceutical compositions and methods for making and using them, including the treatment of immunological disorders, such as autoimmune diseases, and for the targeted elimination of cells, e.g., T lymphocytes and other cells latently infected with a primate immunodeficiency virus, such as a human immunodeficiency virus, e.g., HIV-1.
A bispecific antibody comprising
A method of making a chimeric composition that can specifically bind to a chemokine receptor and a CD3 antigen comprising the following steps:
A method for making a bispecific antibody comprising
Dependencies are inferred from the claim text.